Sociedad Americana de Hirudoterapia

Macin family of antimicrobial proteins combines antimicrobial and nerve repair activities

Biochemistry article published in Journal of Biological Chemistry (2012)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportFarmacología salivalResistencia antimicrobianaJung S, Sönnichsen FD, Hung CW et al. · The Journal of biological chemistry, 2012

Abstract

The tertiary structures of theromacin and neuromacin confirmed the macin protein family as a self-contained family of antimicrobial proteins within the superfamily of scorpion toxin-like proteins. The macins, which also comprise hydramacin-1, are antimicrobially active against Gram-positive and Gram-negative bacteria. Despite high sequence identity, the three proteins showed distinct differences with respect to their biological activity. Neuromacin exhibited a significantly stronger capacity to permeabilize the cytoplasmic membrane of Bacillus megaterium than theromacin and hydramacin-1. Accordingly, it is the only macin that displays pore-forming activity and that was potently active against Staphylococcus aureus. Moreover, neuromacin and hydramacin-1 led to an aggregation of bacterial cells that was not observed with theromacin. Analysis of the molecular surface properties of macins allowed confirmation of the barnacle model as the mechanistic model for the aggregation effect. Besides being antimicrobially active, neuromacin and theromacin, in contrast to hydramacin-1, were able to enhance the repair of leech nerves ex vivo. Notably, all three macins enhanced the viability of murine neuroblastoma cells, extending their functional characteristics. As neuromacin appears to be both a functional and structural chimera of hydramacin-1 and theromacin, the putative structural correlate responsible for the nerve repair capacity in leech was located to a cluster of six amino acid residues using the sequence similarity of surface-exposed regions.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsAntimicrobial Cationic PeptidesBase SequenceCloning, MolecularDisulfidesHumansLeechesMagnetic Resonance SpectroscopyMolecular Sequence DataNeuronsProtein Conformation

Resumen

Tertiary structures of theromacin and neuromacin reveal that leech-derived macin antimicrobial peptides also enhance leech nerve repair and promote murine neuroblastoma viability, expanding their therapeutic profile beyond microbicidal activity.

Por qué esto importa para la hirudoterapia

This study characterized the biological activities of macin family antimicrobial proteins, confirming the macins as a distinct family within the scorpion toxin-like superfamily, with tertiary structures reported for theromacin and neuromacin. The three proteins (theromacin, neuromacin, hydramacin-1) showed distinct antimicrobial profiles against Gram-positive and Gram-negative bacteria, with neuromacin displaying the strongest membrane permeabilization and pore-forming activity against Staphylococcus aureus. Notably, neuromacin and theromacin enhanced leech nerve repair ex vivo, while all three macins enhanced viability of murine neuroblastoma cells. For ASH, this is relevant as it reveals dual antimicrobial and nerve-repair activities in macin proteins associated with leeches. However, the study is preclinical (ex vivo and in vitro), involves non-human cells and tissues, and includes hydramacin-1 from Hydra; there are no therapeutic or clinical data relevant to hirudotherapy.

Citación

Macin family of antimicrobial proteins combines antimicrobial and nerve repair activities.

Jung S, Sönnichsen FD, Hung CW et al. · The Journal of biological chemistry, 2012

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.